BridgeBio Pharma Statistics
Total Valuation
BBIO has a market cap or net worth of $12.82 billion. The enterprise value is $14.38 billion.
Important Dates
The last earnings date was Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BBIO has 195.86 million shares outstanding. The number of shares has increased by 1.99% in one year.
| Current Share Class | 195.86M |
| Shares Outstanding | 195.86M |
| Shares Change (YoY) | +1.99% |
| Shares Change (QoQ) | +0.64% |
| Owned by Insiders (%) | 3.99% |
| Owned by Institutions (%) | 83.50% |
| Float | 152.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 22.11 |
| Forward PS | 11.89 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 24.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.52
| Current Ratio | 1.52 |
| Quick Ratio | 1.40 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.67 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -27.98% |
| Return on Invested Capital (ROIC) | -142.30% |
| Return on Capital Employed (ROCE) | -90.91% |
| Weighted Average Cost of Capital (WACC) | 9.02% |
| Revenue Per Employee | $691,249 |
| Profits Per Employee | -$860,014 |
| Employee Count | 839 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.53 |
Taxes
In the past 12 months, BBIO has paid $435,000 in taxes.
| Income Tax | 435,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +84.66% in the last 52 weeks. The beta is 0.97, so BBIO's price volatility has been similar to the market average.
| Beta (5Y) | 0.97 |
| 52-Week Price Change | +84.66% |
| 50-Day Moving Average | 70.70 |
| 200-Day Moving Average | 66.58 |
| Relative Strength Index (RSI) | 43.46 |
| Average Volume (20 Days) | 3,169,072 |
Short Selling Information
The latest short interest is 24.16 million, so 12.34% of the outstanding shares have been sold short.
| Short Interest | 24.16M |
| Short Previous Month | 24.03M |
| Short % of Shares Out | 12.34% |
| Short % of Float | 15.82% |
| Short Ratio (days to cover) | 8.19 |
Income Statement
In the last 12 months, BBIO had revenue of $579.96 million and -$721.55 million in losses. Loss per share was -$3.74.
| Revenue | 579.96M |
| Gross Profit | 551.70M |
| Operating Income | -504.22M |
| Pretax Income | -729.45M |
| Net Income | -721.55M |
| EBITDA | -498.88M |
| EBIT | -504.22M |
| Loss Per Share | -$3.74 |
Full Income StatementBalance Sheet
The company has $940.19 million in cash and $2.49 billion in debt, with a net cash position of -$1.55 billion or -$7.92 per share.
| Cash & Cash Equivalents | 940.19M |
| Total Debt | 2.49B |
| Net Cash | -1.55B |
| Net Cash Per Share | -$7.92 |
| Equity (Book Value) | -2.27B |
| Book Value Per Share | -11.64 |
| Working Capital | 424.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$443.95 million and capital expenditures -$1.17 million, giving a free cash flow of -$445.12 million.
| Operating Cash Flow | -443.95M |
| Capital Expenditures | -1.17M |
| Depreciation & Amortization | 5.34M |
| Net Borrowing | 932.50M |
| Free Cash Flow | -445.12M |
| FCF Per Share | -$2.27 |
Full Cash Flow StatementMargins
Gross margin is 95.13%, with operating and profit margins of -86.94% and -124.41%.
| Gross Margin | 95.13% |
| Operating Margin | -86.94% |
| Pretax Margin | -125.78% |
| Profit Margin | -124.41% |
| EBITDA Margin | -86.02% |
| EBIT Margin | -86.94% |
| FCF Margin | n/a |
Dividends & Yields
BBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.99% |
| Shareholder Yield | -1.99% |
| Earnings Yield | -5.63% |
| FCF Yield | -3.47% |
Dividend DetailsAnalyst Forecast
The average price target for BBIO is $102.71, which is 56.86% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $102.71 |
| Price Target Difference | 56.86% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 24 |
| Revenue Growth Forecast (3Y) | 68.94% |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BBIO has an Altman Z-Score of -2.72 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.72 |
| Piotroski F-Score | 2 |
